Nasus Pharma Statistics
Total Valuation
Nasus Pharma has a market cap or net worth of $46.84 million. The enterprise value is $35.13 million.
| Market Cap | 46.84M |
| Enterprise Value | 35.13M |
Important Dates
The last earnings date was Monday, August 17, 2026, before market open.
| Earnings Date | Aug 17, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Nasus Pharma has 11.71 million shares outstanding. The number of shares has increased by 38.03% in one year.
| Current Share Class | 11.71M |
| Shares Outstanding | 11.71M |
| Shares Change (YoY) | +38.03% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 34.25% |
| Owned by Institutions (%) | 10.34% |
| Float | 4.84M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 4.26 |
| P/TBV Ratio | 4.26 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.77, with a Debt / Equity ratio of 0.01.
| Current Ratio | 8.77 |
| Quick Ratio | 8.42 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -316.04% and return on invested capital (ROIC) is -135.43%.
| Return on Equity (ROE) | -316.04% |
| Return on Assets (ROA) | -96.73% |
| Return on Invested Capital (ROIC) | -135.43% |
| Return on Capital Employed (ROCE) | -91.70% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.51M |
| Employee Count | 7 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -51.81% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -51.81% |
| 50-Day Moving Average | 3.26 |
| 200-Day Moving Average | 4.58 |
| Relative Strength Index (RSI) | 69.84 |
| Average Volume (20 Days) | 16,353 |
Short Selling Information
The latest short interest is 160,076, so 1.37% of the outstanding shares have been sold short.
| Short Interest | 160,076 |
| Short Previous Month | 172,140 |
| Short % of Shares Out | 1.37% |
| Short % of Float | 3.31% |
| Short Ratio (days to cover) | 13.11 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -10.13M |
| Pretax Income | -10.56M |
| Net Income | -10.55M |
| EBITDA | n/a |
| EBIT | -10.13M |
| Earnings Per Share (EPS) | -$1.07 |
Balance Sheet
The company has $11.82 million in cash and $103,000 in debt, with a net cash position of $11.72 million or $1.00 per share.
| Cash & Cash Equivalents | 11.82M |
| Total Debt | 103,000 |
| Net Cash | 11.72M |
| Net Cash Per Share | $1.00 |
| Equity (Book Value) | 11.00M |
| Book Value Per Share | 0.94 |
| Working Capital | 10.91M |
Cash Flow
In the last 12 months, operating cash flow was -$10.52 million and capital expenditures -$18,000, giving a free cash flow of -$10.54 million.
| Operating Cash Flow | -10.52M |
| Capital Expenditures | -18,000 |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | -10.54M |
| FCF Per Share | -$0.90 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Nasus Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -38.03% |
| Shareholder Yield | -38.03% |
| Earnings Yield | -22.51% |
| FCF Yield | -22.50% |
Analyst Forecast
The average price target for Nasus Pharma is $19.67, which is 391.75% higher than the current price. The consensus rating is "Buy".
| Price Target | $19.67 |
| Price Target Difference | 391.75% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |